

Mauro Biffi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9379266/publications.pdf>

Version: 2024-02-01

174
papers

5,778
citations

109264

35
h-index

95218

68
g-index

174
all docs

174
docs citations

174
times ranked

3807
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
2	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
3	Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 241-248.	0.8	341
4	Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. <i>New England Journal of Medicine</i> , 2019, 380, 1895-1905.	13.9	251
5	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European EHRA expert consensus statement and a practical guideline on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2021, 23, 983-1008.	0.7	216
6	A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long detection window programming in patients with Left Ventricular dysfunction, Non-ischemic etiology in primary prevention treated with a biventricular ICD] study. <i>European Heart Journal</i> , 2009, 30, 2758-2767.	1.0	149
7	Dynamic Electrophysiological Behavior of Human Atria During Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1995, 92, 1193-1202.	1.6	148
8	Alternate Site Cardiac Resynchronization (ALSYNCRONIZATION): a prospective and multicentre study of left ventricular endocardial pacing for cardiac resynchronization therapy. <i>European Heart Journal</i> , 2016, 37, 2118-2127.	1.0	127
9	Phrenic Stimulation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 402-410.	2.1	114
10	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European EHRA expert consensus statement and a practical guideline on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2021, 23, 983-1008.	0.6	111
11	A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: The Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. <i>American Heart Journal</i> , 2010, 159, 1052-1058.e1.	0.7	92
12	The MONitoring Resynchronization dEVICES and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring. <i>Journal of Medical Internet Research</i> , 2013, 15, e167.	1.2	85
13	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1617-1623.	2.1	83
14	From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. <i>Expert Review of Medical Devices</i> , 2013, 10, 551-573.	3.3	79
15	A review of multisite pacing to achieve cardiac resynchronization therapy. <i>Europace</i> , 2015, 17, 7-17.	1.4	78
16	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 1124.	0.7	75
17	Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: a prospective study. <i>Europace</i> , 2006, 8, 216-220.	1.6	61
18	Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: a prospective study. <i>Europace</i> , 2006, 8, 216-220.	0.7	55

#	ARTICLE	IF	CITATIONS
19	Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy: A multicenter international registry of the WiSE-CRT pacing system. <i>Heart Rhythm</i> , 2020, 17, 1291-1297.	0.3	55
20	The value of ECG changes in risk stratification of COVID-19 patients. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12815.	0.5	54
21	Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. <i>Europace</i> , 2008, 10, 1288-1295.	0.7	53
22	Clinical implications of left superior vena cava persistence in candidates for pacemaker or cardioverter-defibrillator implantation. <i>Heart and Vessels</i> , 2009, 24, 142-146.	0.5	53
23	Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2011, 13, 868-876.	2.9	53
24	Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy. <i>European Heart Journal</i> , 2008, 30, 89-97.	1.0	51
25	Telecardiology and Remote Monitoring of Implanted Electrical Devices: The Potential for Fresh Clinical Care Perspectives. <i>Journal of General Internal Medicine</i> , 2008, 23, 73-77.	1.3	50
26	Occurrence of phrenic nerve stimulation in cardiac resynchronization therapy patients: the role of left ventricular lead type and placement site. <i>Europace</i> , 2013, 15, 77-82.	0.7	49
27	Actual Pacemaker Longevity: The Benefit of Stimulation by Automatic Capture Verification. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 873-881.	0.5	47
28	From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. <i>Expert Review of Medical Devices</i> , 2011, 8, 235-255.	1.4	47
29	Meta-analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all-cause mortality and hospitalizations. <i>European Journal of Heart Failure</i> , 2012, 14, 652-660.	2.9	45
30	Cardiac device therapy in patients with left ventricular dysfunction and heart failure: a real-world data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital). <i>European Journal of Heart Failure</i> , 2016, 18, 693-702.	2.9	45
31	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 194-205.	3.3	45
32	Performance of a novel left ventricular lead with short bipolar spacing for cardiac resynchronization therapy: Primary results of the Attain Performa Quadripolar Left Ventricular Lead Study. <i>Heart Rhythm</i> , 2015, 12, 751-758.	0.3	44
33	Predictors of long-term survival free from relapses after extraction of infected CIED. <i>Europace</i> , 2018, 20, 1018-1027.	0.7	43
34	Benefits in Projected Pacemaker Longevity and in Pacing Related Costs Conferred by Automatic Threshold Tracking. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1783-1787.	0.5	42
35	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. <i>European Journal of Heart Failure</i> , 2018, 20, 1472-1481.	2.9	39
36	Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). <i>Heart Rhythm</i> , 2016, 13, 1987-1992.	0.3	38

#	ARTICLE	IF	CITATIONS
37	Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: An analysis of current clinical practice and a comparison with transvenous ICD reimplantation. <i>Heart Rhythm</i> , 2019, 16, 564-571.	0.3	37
38	Device Longevity in a Contemporary Cohort of ICD/CRT- Δ ED Patients Undergoing Device Replacement. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 840-845.	0.8	35
39	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 182-188.	0.9	33
40	Implantation technique and optimal subcutaneous defibrillator chest position: a PRAETORIAN score-based study. <i>Europace</i> , 2020, 22, 1822-1829.	0.7	31
41	The "Subtle" connection between development of cardiac implantable electrical device infection and survival after complete system removal: An observational prospective multicenter study. <i>International Journal of Cardiology</i> , 2018, 250, 146-149.	0.8	30
42	Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?. <i>Europace</i> , 2014, 16, 533-540.	0.7	28
43	Subcutaneous implantable cardioverter defibrillator implantation: An analysis of Italian clinical practice and its evolution. <i>International Journal of Cardiology</i> , 2018, 272, 162-167.	0.8	28
44	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. <i>Europace</i> , 2020, 22, 1855-1863.	0.7	28
45	Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience. <i>Heart Rhythm</i> , 2021, 18, 2050-2058.	0.3	28
46	Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 61-67.	0.6	27
47	Does the CHA ₂ DS ₂ -VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices. <i>Heart Rhythm</i> , 2018, 15, 971-979.	0.3	26
48	Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD). <i>Europace</i> , 2018, 20, 979-985.	0.7	26
49	Real-life outcome of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry. <i>Europace</i> , 2019, 21, 1527-1536.	0.7	25
50	Clinical Evaluation of Morphology Discrimination: An Algorithm for Rhythm Discrimination in Cardioverter Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 994-1001.	0.5	24
51	Impact on All-Cause and Cardiovascular Mortality of Cardiac Implantable Electronic Device Complications. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 382-392.	1.3	24
52	Transvenous Low Energy Internal Cardioversion for Atrial Fibrillation: A Review of Clinical Applications and Future Developments. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 99-107.	0.5	23
53	Automatic Management of Left Ventricular Stimulation: Hints for Technologic Improvement. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 346-353.	0.5	23
54	Phrenic stimulation management in CRT patients: are we there yet?. <i>Current Opinion in Cardiology</i> , 2011, 26, 12-16.	0.8	23

#	ARTICLE	IF	CITATIONS
55	Long-term RV Threshold Behavior by Automated Measurements: Safety is the Standpoint of Pacemaker Longevity!. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 89-95.	0.5	23
56	Clinical Performance of a Ventricular Automatic Capture Verification Algorithm. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 933-937.	0.5	22
57	Evolution of pacing for bradycardia: Autocapture. Country Review Ukraine, 2007, 9, 123-132.	0.8	22
58	Atrial Threshold Variability: Implications for Automatic Atrial Stimulation Algorithms. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1445-1454.	0.5	22
59	New left ventricular active fixation lead: The experience of lead extraction. Indian Heart Journal, 2015, 67, S97-S99.	0.2	22
60	Clinically oriented device programming in bradycardia patients: part 1 (sinus node disease). Proposals from AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Journal of Cardiovascular Medicine, 2018, 19, 161-169.	0.6	22
61	Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1201-1208.	0.5	21
62	Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. Europace, 2016, 18, 1366-1373.	0.7	21
63	Effect of Bipolar Electrode Spacing on Phrenic Nerve Stimulation and Left Ventricular Pacing Thresholds. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 815-820.	2.1	20
64	Benefits of left ventricular endocardial pacing comparing failed implants and prior non-responders to conventional cardiac resynchronization therapy: A subanalysis from the ALSYNC study. International Journal of Cardiology, 2018, 259, 88-93.	0.8	20
65	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace, 2019, 21, 636-644.	0.7	20
66	Oral Loading with Propafenone: A Placebo-Controlled Study in Elderly and Nonelderly Patients with Recent Onset Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2465-2469.	0.5	19
67	Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis. Heart Rhythm, 2021, 18, 2080-2086.	0.3	19
68	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. Value in Health, 2021, 24, 930-938.	0.1	19
69	Short-spaced dipole for managing phrenic nerve stimulation in patients with CRT: The œphrenic nerve mapping and stimulation EP-catheter study. Heart Rhythm, 2013, 10, 39-45.	0.3	18
70	Cardiac resynchronization therapy and cardiac sympathetic function. European Journal of Clinical Investigation, 2015, 45, 792-799.	1.7	18
71	Detect Long-term Complications After ICD Replacement (DECODE): Rationale and Study Design of a Multicenter Italian Registry. Clinical Cardiology, 2015, 38, 577-584.	0.7	17
72	Automatic management of atrial and ventricular stimulation in a contemporary unselected population of pacemaker recipients: the ESSENTIAL Registry. Europace, 2016, 18, 1551-1560.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Clinically oriented device programming in bradycardia patients: part 2 (atrioventricular blocks and) Tj ETQq1 1 0.784314 rgBT /Overlo	0.6	17
74	Are Atrial High-Rate Episodes Associated With Increased Risk of Ventricular Arrhythmias and Mortality?. JACC: Clinical Electrophysiology, 2019, 5, 1197-1208.	1.3	17
75	Rate and impact on patient outcome and healthcare utilization of complications requiring surgical revision: Subcutaneous versus transvenous implantable defibrillator therapy. Journal of Cardiovascular Electrophysiology, 2021, 32, 1712-1723.	0.8	17
76	Arrhythmia discrimination by physician and defibrillator: Importance of atrial channel. International Journal of Cardiology, 2012, 154, 134-140.	0.8	16
77	Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD. Indian Heart Journal, 2015, 67, 56-59.	0.2	16
78	Leadless left ventricular endocardial pacing: a real alternative or a luxury for a few?. Cardiovascular Diagnosis and Therapy, 2018, 8, 530-533.	0.7	16
79	How to truly value implantable cardioverter-defibrillators technology: Up-front cost or daily cost?. International Journal of Technology Assessment in Health Care, 2011, 27, 201-206.	0.2	15
80	The OPTI-MIND study: a prospective, observational study of pacemaker patients according to pacing modality and primary indications. Europace, 2014, 16, 689-697.	0.7	15
81	Cost-effectiveness of implantable cardioverter-defibrillator in today's world. Indian Heart Journal, 2014, 66, S101-S104.	0.2	15
82	The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: Results from the THINGS registry. Journal of Cardiovascular Electrophysiology, 2020, 31, 846-853.	0.8	15
83	Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators: A propensity-matched analysis from a multicenter European registry. Heart Rhythm, 2022, 19, 1109-1115.	0.3	15
84	Left ventricular pacing by automatic capture verification. Europace, 2007, 9, 1177-1181.	0.7	14
85	Holter ECG for pacemaker/defibrillator carriers: what is its role in the era of remote monitoring?. Heart, 2015, 101, 1272-1278.	1.2	14
86	Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise. Heart Lung and Circulation, 2016, 25, 476-483.	0.2	14
87	Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis. Europace, 2018, 20, 1475-1483.	0.7	14
88	Comparison of cryoballoon and radiofrequency ablation techniques for atrial fibrillation: a meta-analysis. Journal of Cardiovascular Medicine, 2018, 19, 725-738.	0.6	14
89	Less invasive ventricular enhancement (LIVE) as potential therapy for ischaemic cardiomyopathy end-stage heart failure. Journal of Thoracic Disease, 2019, 11, S921-S928.	0.6	14
90	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX, antibiotic envelope. Europace, 2021, 23, iv33-iv44.	0.7	14

#	ARTICLE	IF	CITATIONS
91	Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study. <i>Heart Rhythm</i> , 2021, 18, 2072-2079.	0.3	14
92	Transvenous Cardioverter-Defibrillator Implantation in a Patient with Tricuspid Mechanical Prosthesis. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 329-331.	0.8	13
93	Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks. <i>Clinical Cardiology</i> , 2019, 42, 612-617.	0.7	13
94	Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. <i>Current Pharmaceutical Design</i> , 2017, 23, 944-951.	0.9	13
95	Less is more: Can we achieve cardiac resynchronization with 2 leads only?. <i>International Journal of Cardiology</i> , 2017, 249, 184-190.	0.8	12
96	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 263.	1.2	12
97	Bipolar active fixation left ventricular lead or quadripolar passive fixation lead? An Italian multicenter experience. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 192-200.	0.6	12
98	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. <i>Heart</i> , 2022, 108, 54-60.	1.2	12
99	Predictors of Atrial Defibrillation Threshold in Internal Cardioversion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1898-1901.	0.5	11
100	Is ventricular sensing always right, when it is left?. <i>Clinical Cardiology</i> , 2018, 41, 1238-1245.	0.7	11
101	Pacing devices to treat bradycardia: current status and future perspectives. <i>Expert Review of Medical Devices</i> , 2021, 18, 161-177.	1.4	11
102	Clinical Evaluation of Two Different Evoked Response Sensing Methods for Automatic Capture Detection in the Left Ventricle. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 865-873.	0.5	10
103	ICD programming. <i>Indian Heart Journal</i> , 2014, 66, S88-S100.	0.2	10
104	Percutaneous Pulmonary Artery Venting via Jugular Vein While on Peripheral Extracorporeal Life Support. <i>ASAIO Journal</i> , 2020, 66, e50-e54.	0.9	10
105	Clinical impact of defibrillation testing in a real-world S-ICD population: Data from the ELISIR registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 468-476.	0.8	10
106	Is 40 Joules Enough to Successfully Defibrillate With Subcutaneous Implantable Cardioverter-Defibrillators?. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 767-776.	1.3	10
107	Long-term progression of rhythm and conduction disturbances in pacemaker recipients: findings from the Pacemaker Expert Programming study. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 357-365.	0.6	9
108	Repolarization Changes in a Double-Blind Crossover Study of Dofetilide Versus Sotalol in the Treatment of Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1935-1938.	0.5	8

#	ARTICLE	IF	CITATIONS
109	Pacing with capture verification in candidates for resynchronisation therapy: A feasibility study. <i>Europace</i> , 2005, 7, 255-265.	0.7	8
110	Left Ventricular Reverse Remodeling Elicited by a Quadripolar Lead: Results from the Multicenter Per4mer Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 250-260.	0.5	8
111	Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation. <i>International Journal of Cardiology</i> , 2017, 230, 275-280.	0.8	8
112	Rate-responsive pacing and atrial high rate episodes in cardiac resynchronization therapy patients: Is low heart rate the key?. <i>Clinical Cardiology</i> , 2019, 42, 820-828.	0.7	8
113	Time to therapy delivery and effectiveness of the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2019, 16, 1531-1537.	0.3	8
114	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 123-132.	1.4	8
115	Risk of syncopal recurrences in patients treated with permanent pacing for bradyarrhythmic syncope: role of correlation between symptoms and electrocardiogram findings. <i>Europace</i> , 2020, 22, 1729-1736.	0.7	8
116	Diagnosis and management of subcutaneous implantable cardioverter-defibrillator infections based on process mapping. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 958-965.	0.5	8
117	Causes of syncopal recurrences in patients treated with permanent pacing for bradyarrhythmic syncope: Findings from the SYNCOPACED registry. <i>Heart Rhythm</i> , 2021, 18, 770-777.	0.3	8
118	Clinical Management of Atrial Fibrillation. <i>Chest</i> , 2011, 140, 843-845.	0.4	7
119	Clinically guided pacemaker choice and setting: pacemaker expert programming study. <i>Europace</i> , 2016, 19, euw256.	0.7	7
120	Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. <i>International Journal of Cardiology</i> , 2018, 261, 73-77.	0.8	7
121	The ECG Belt for CRT response trial: Design and clinical protocol. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1063-1071.	0.5	7
122	Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal cardioversion in patients with chronic persistent atrial fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 1999, 13, 507-511.	1.3	6
123	Neurocardiogenic syncope in selected pediatric patients-natural history during long-term follow-up and effect of prophylactic pharmacological therapy. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 161-167.	1.3	6
124	Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators. <i>Europace</i> , 2008, 10, 918-925.	0.7	6
125	Manufacturer change and risk of system-related complications after implantable cardioverter defibrillator replacement. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 968-975.	0.6	6
126	External implantable defibrillator as a bridge to reimplant after explant for infection: Experience from two centers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 532-535.	0.5	6

#	ARTICLE	IF	CITATIONS
127	Long-term electrical performance of Attain Performa quadripolar left ventricular leads with all steroid-eluting electrodes: Results from a large worldwide clinical trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 920-926.	0.5	6
128	Impact of pacemaker longevity on expected device replacement rates: Results from computer simulations based on a multicenter registry (ESSENTIAL). <i>Clinical Cardiology</i> , 2018, 41, 1185-1191.	0.7	6
129	The never-ending story of CIED infection prevention: Shall we WRAP it and go?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1191-1196.	0.8	6
130	Seasonal trend of ventricular arrhythmias in a nationwide remote monitoring database of implantable defibrillators and cardiac resynchronization devices. <i>International Journal of Cardiology</i> , 2019, 275, 104-106.	0.8	6
131	Lamin A/C Missense Mutation R216C Pinpoints Overlapping Features Between Brugada Syndrome and Laminopathies. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002751.	1.6	6
132	Lead Abandonment and Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) Implantation in a Cohort of Patients With ICD Lead Malfunction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 692943.	1.1	6
133	Intraprocedural PRAETORIAN score for early assessment of S-ICD implantation: A proof-of-concept study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 3035-3041.	0.8	6
134	Abnormal Cardiac Innervation in Patients with Idiopathic Ventricular Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 357-360.	0.5	5
135	Patient selection for ambulatory cardiac monitoring in the Indian healthcare environment. <i>Heart Asia</i> , 2013, 5, 112-119.	1.1	5
136	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. <i>Europace</i> , 2017, 19, 1767-1775.	0.7	5
137	Long-term outcomes after prophylactic ICD and CRT-D implantation in nonischemic patients: Analysis from a nationwide database of daily remote monitoring transmissions. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1626-1635.	0.8	5
138	Shoulder Function After Cardioverter-Defibrillator Implantation: 5-Year Follow-up. <i>Annals of Thoracic Surgery</i> , 2020, 110, 608-614.	0.7	5
139	Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: A Propensity-Matched Case-Control Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, CIRCEP121010381.	2.1	5
140	The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2022, 19, 1958-1964.	0.3	5
141	Heart failure after myocardial revascularization: Risk markers. <i>International Journal of Cardiology</i> , 2005, 105, 11-14.	0.8	4
142	Lead choice in cardiac implantable electronic devices: an Italian survey promoted by AIAC (Italian Tj ETQq0 0 0 rgBT JOverlock 10 Tf 50	1.4	4
143	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. <i>Expert Review of Medical Devices</i> , 2020, 17, 297-308.	1.4	4
144	Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation. <i>ESC Heart Failure</i> , 2021, , .	1.4	4

#	ARTICLE	IF	CITATIONS
145	DDD and single-lead VDD pacing: Evaluation of atrial signal dynamic changes. <i>Clinical Cardiology</i> , 2000, 23, 678-680.	0.7	3
146	Wireless Endocardial Atrial (and Ventricular) Sensing with no Implanted Power Source: a Proposal. <i>Journal of Medical Systems</i> , 2019, 43, 159.	2.2	3
147	Temporal patterns of premature atrial complexes predict atrial fibrillation occurrence in bradycardia patients continuously monitored through pacemaker diagnostics. <i>Internal and Emergency Medicine</i> , 2020, 15, 599-606.	1.0	3
148	Mortality after cardioverter-defibrillator replacement: Results of the DECODE survival score index. <i>Heart Rhythm</i> , 2021, 18, 411-418.	0.3	3
149	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 262-269.	0.5	3
150	Internal Low Energy Atrial Cardioversion: Efficacy and Safety in Older Patients with Chronic Persistent Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 80-84.	1.3	2
151	Electrical manipulation of the failing heart. <i>Heart Failure Reviews</i> , 2018, 23, 885-896.	1.7	2
152	Cardiac Stimulation in the Third Millennium: Where Do We Head from Here?. <i>Hearts</i> , 2021, 2, 15-35.	0.4	2
153	Management of patients explanted for implantable cardioverter defibrillator infections: Bridge therapy with external temporary ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1884-1889.	0.5	2
154	Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing). <i>Biology</i> , 2022, 11, 265.	1.3	2
155	Process Mapping Strategies to Prevent Subcutaneous Implantable Cardioverter-Defibrillator Infections. <i>Journal of Cardiovascular Electrophysiology</i> , 0, , .	0.8	2
156	Pacing-induced torsades de pointes after the short-long-short sequence in a patient with a biventricular defibrillator: What is the mechanism?. <i>Heart Rhythm</i> , 2014, 11, 728-731.	0.3	1
157	Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers. <i>International Journal of Clinical Practice</i> , 2021, 75, e13820.	0.8	1
158	Circadian periodicity affects the type of ventricular arrhythmias and efficacy of implantable defibrillator therapies. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2528-2535.	0.8	1
159	Cum Grano Salis: Cardiac Sarcoidosis as a Perfect Mimic of Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012355.	1.3	1
160	Ventricular Fibrillation Triggered by Earthquake During the Accumoli-Amatrice Disaster in Italy. <i>Circulation Journal</i> , 2017, 81, 759-760.	0.7	1
161	Atrial remodeling: evolving concepts. <i>Indian Pacing and Electrophysiology Journal</i> , 2003, 3, 81-7.	0.3	1
162	His Bundle pacing for congenital complete AV block: An attempt to fix a broken heart?. <i>Annals of Noninvasive Electrocardiology</i> , 2022, , e12895.	0.5	1

#	ARTICLE	IF	CITATIONS
163	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 243-246.	1.0	0
164	Response:. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 389-390.	0.5	0
165	Atrial Fibrillation. Chest, 2012, 141, 290-292.	0.4	0
166	Against all odds: Targeted pacing site for resynchronization therapy by venoplasty and active fixation lead. Indian Heart Journal, 2015, 67, 574-576.	0.2	0
167	Oral loading of propafenone: restoring its role before restoring rhythm. Europace, 2017, 19, 1903-1903.	0.7	0
168	Automatic verification of capture in the scenario of His bundle pacing: still an unmet need?. Journal of Cardiovascular Electrophysiology, 2019, 30, 2110-2112.	0.8	0
169	Cost-effectiveness of cardiac resynchronization therapy. Journal of Medical Economics, 2020, 23, 1375-1378.	1.0	0
170	A Historical Perspective of Cardiac Implantable Electronic Device Infection: How a Menace Can Drive Technological and Clinical Improvement. Hearts, 2021, 2, 202-212.	0.4	0
171	Prevention of Infection: Indications, Device Programming, Patient Follow-Up. , 2020, , 209-229.		0
172	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. Journal of Atrial Fibrillation, 2013, 5, 748.	0.5	0
173	Combined Use of S-ICD and Absorbable Antibacterial Envelopes: A Proof-of-concept Study. Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	0.6	0
174	Long-term follow-up of patients with a quadripolar active fixation left ventricular lead. An Italian multicenter experience. Journal of Cardiovascular Electrophysiology, 0, , .	0.8	0